This "Change the Story" Technology Stock Zoomed 45% in Five Days – and Here's Why

We've had some queries about TrovaGene Inc. (Nasdaq: TROV) after shares of our "Liquid Biopsy" recommendation rose five days in a row - an advance that took the shares up nearly 45% over those five trading sessions.

And though we predicted this - and have devoted quite a bit of analysis to this stock of late - we're always glad to respond to inquiries... especially when it comes to a stock like this one that we believe offers a massive possible upside.

This will be a relatively short update.

And we'll start with the facts.

Leave a Reply

Your email address will not be published. Required fields are marked *


Some HTML is OK